VIVOSIM LABS INC (VIVS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.15+5.99%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VIVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
VIVS — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer met the requirement to maintain a mi…
Why it matters: The company reported $10.1 million in cash on Aug. 3, after a milestone payment and financing. Later filings will show how long that cash lasts.
Worry ifA quarterly filing shows cash below $10.1 million and no new cash from operations or financing.
Less concerning ifA quarterly filing shows cash of at least $10.1 million. Operating losses are below the prior $2.76 million.
Why it matters: Nasdaq said the share price missed its minimum bid rule. A compliance update will show whether the listing risk has eased.
Worry ifA company filing says Nasdaq found the bid-price rule was met. Or, it extended the deadline after the company met the rule.
Less concerning ifA company filing says Nasdaq will delist the shares. Or, the company says it still failed the bid-price rule after the deadline.
Why it matters: The report can test the 500% growth goal and show whether losses are easing. Recent operating losses remained large.
Watch forThe report shows revenue growth tracking toward 500% for FY2027 and a smaller operating loss than $2.76 million.
Also watch forThe report shows revenue growth below the pace needed for 500% in FY2027, or an operating loss above $2.76 million.
Why it matters: VivoSim tied its FY2027 growth goal to sales of NAM testing services. Revenue reports will show whether that growth is taking hold.
Supportive ifA FY2027 report shows revenue up at least 500% year over year.
Worry ifA FY2027 report shows revenue growth below 500%, or revenue falls year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$326 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $1,185 loss on $10,000 · 11.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,508 loss on $10,000 · 95.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The July deal brought in cash but included warrants and a lower strike price for older warrants. New shares can dilute existing holders.
Worry ifA filing shows more common shares issued from the July warrants, beyond the 9.9 million shares issued by July 31.
Less concerning ifA filing shows no more common shares came from the July warrants and no new financing linked to shares.